GT Biopharma Inc (NASDAQ:GTBP) — Market Cap & Net Worth
Market Cap & Net Worth: GT Biopharma Inc (GTBP)
GT Biopharma Inc (NASDAQ:GTBP) has a market capitalization of $15.20 Million ($15.20 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25979 globally and #5383 in its home market, demonstrating a 9.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GT Biopharma Inc's stock price $0.46 by its total outstanding shares 36062904 (36.06 Million). Review GTBP current and long-term liabilities to assess the company's total debt and financial obligations.
GT Biopharma Inc Market Cap History: 2015 to 2026
GT Biopharma Inc's market capitalization history from 2015 to 2026. Data shows change from $17.66 Trillion to $16.55 Million (-73.42% CAGR).
Index Memberships
GT Biopharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #737 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2422 of 3165 |
Weight: GT Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GT Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GT Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3031286.10x
GT Biopharma Inc's market cap is 3031286.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $81.84 Billion | $27.00K | -$144.17 Million | 3031286.10x | N/A |
Competitor Companies of GTBP by Market Capitalization
Companies near GT Biopharma Inc in the global market cap rankings as of June 18, 2026.
Key companies related to GT Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
GT Biopharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, GT Biopharma Inc's market cap moved from $17.66 Trillion to $ 16.55 Million, with a yearly change of -73.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.55 Million | -41.54% |
| 2025 | $28.32 Million | -74.26% |
| 2024 | $109.99 Million | -60.13% |
| 2023 | $275.88 Million | -71.21% |
| 2022 | $958.23 Million | -70.96% |
| 2021 | $3.30 Billion | -57.69% |
| 2020 | $7.80 Billion | +423.46% |
| 2019 | $1.49 Billion | -87.54% |
| 2018 | $11.95 Billion | -85.39% |
| 2017 | $81.84 Billion | -84.08% |
| 2016 | $514.24 Billion | -97.09% |
| 2015 | $17.66 Trillion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of GT Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.20 Million USD |
| MoneyControl | $15.20 Million USD |
| MarketWatch | $15.20 Million USD |
| marketcap.company | $15.20 Million USD |
| Reuters | $15.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more